替吉奥单药三线治疗老年晚期胰腺癌1例报道
被引量:5
摘要
胰腺癌是全世界致死率最高的恶性肿瘤之一,5年生存率仅5%,中位生存期约6—8月。虽然外科手术是胰腺癌唯一的治愈手段,但多数患者因诊断时分期太晚而无法手术切除。即使可手术切除的患者,
出处
《实用肿瘤杂志》
CAS
2014年第1期90-92,共3页
Journal of Practical Oncology
参考文献10
-
1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2010 [ J]. Cancer J Clin,2010,60(5 ) :277 - 300.
-
2Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine-based combination therapy in the manage- ment of advanced pancreatic cancer: A meta-analysis of randomised trials [ J ]. Euro J Cancer,2013,49 (3) :593 - 603.
-
3Yamagishi Y, Higuchi H, Izumiya M, et al. Gemcitabine as first-line chemotherapy in elderly patients with unresec- table pancreatic carcinoma [ J ]. J Gastroenterol, 2010,45 (11) :1146 - 1154.
-
4Hwang IG, Jang JS, Oh SY, et al. A phase 11 trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer[ J]. Invest New Drags,2012, 30:2371 - 2376.
-
5Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: Randomized phase IT[ trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer [ J ]. J Clin Oncol,2013,31 ( 15 ) : 4008.
-
6吴莉莉,楼文晖,曾昭冲,曾蒙苏,李婷婷,姬巍.替吉奥同步放疗治疗局部晚期和复发性胰腺癌的Ⅱ期临床试验[J].上海医学,2011,34(5):367-370. 被引量:11
-
7Kim HM,Bang S,Park JY,et al. Phase U trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer [ J ]. Cancer Chemother Pharmacol, 2009,63 (3) :535 - 541.
-
8Nakai Y, Isayama H, Sasaki T, et al. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan [ J ] Jpn J Clin Oncol, 2010,40 ( 8 ) : 774 - 780.
-
9Akiko T,Akira F, Narikazu B, et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure[J [. Jpn J Clin Oncol, 2010,40(6) : 567 - 572.
-
10Sudo K, Yamaguchi T, Nakamura K, et al. Phase H study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer [ J ]. Cancer Chemother Pharmacol,2011,67(2) :249 - 254.
二级参考文献11
-
1CRANE C H, VARADHACHARY G, PISTERS P W, et al. Future chemoradiation strategies in pancreatic cancer EJ~. Semin Oncol, 2007, 34: 335-346.
-
2Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone[J]. J Natl Cancer Inst, 1988, 80: 751-755.
-
3REGINE W F, WINTER K W, ABRAMS R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma[J]. J Clin Oncol, 2006,24 : 4007.
-
4MOERTEL C G, FRYTAK S, HAHN R G, et al. Therapy of locally unresectable pancreatic carcinoma., a randomized comparison of high dose (6000 rads ) radiation alone, moderate dose radiation (4000 fads q-5-fluorouracil), and high dose radiation q- 5-fluorouracil: The Gastrointestinal Tumor Study Group [J]. Cancer, 1981, 48: 1705-1710.
-
5KIM H M, BANGS, PARKJ Y, et al. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer [J]. Cancer Chemother Pharmacol, 2009, 63: 535-541.
-
6AUPER1N A, LE PECHOUX C, ROLLAND E, et al. Meta analysis of concomitant versus sequential radiochemotherapy in locally advanced non small-cell lung cancer [J]. J Clin Oneol, 2010, 28:2181-2190.
-
7FUJITA K, NAKAYAMA H, ICHIKAWA W, et al.Pharmacokinetics of 5 fluorouracil in elderly Japanese patients with cancer treated with S-l (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro 2, 4 dihydroxypyridine) [J]. Drug Metab Dispos, 2009, 37: 1375-1377.
-
8SUDO K, YAMAGUCHI T, ISHIHARA T, et al. Phase 11 Study of Oral S-1 and Concurrent Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer [J]. Int J Radiat Oncol Biol Phys, 2011, 80:119 125.
-
9BJERREGAARD J K, MORTENSEN M B, JENSEN H A, et al. Long term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer [J]. Radiother Oned, 2009, 92:226- 230.
-
10楼文晖.胰腺癌的非手术治疗进展[J].中国实用外科杂志,2008,28(2):90-92. 被引量:4
共引文献10
-
1张松,单国用,刘兴安,侯继院,白桦.局部晚期胰腺癌替吉奥联合三维适形放疗的临床观察[J].中华肿瘤防治杂志,2012,19(12):931-933. 被引量:9
-
2袁欣,胡丹,廖联明.CNKI数据库中肿瘤治疗的临床随机对照试验文献评价[J].肿瘤学杂志,2013(8):639-643. 被引量:1
-
3叶云飞,杨倞,孟岩.调强放疗联合替吉奥化疗局部晚期胰腺癌临床观察[J].中华肿瘤防治杂志,2013,20(22):1759-1762. 被引量:6
-
4朱奇,康静波,聂青,吴苏冬,李启亮.替吉奥联合体部伽玛刀治疗局部晚期胰腺癌的临床观察[J].肿瘤研究与临床,2014,26(9):617-619. 被引量:7
-
5高波,李兴华.替吉奥抗癌治疗的临床研究进展[J].中国新药与临床杂志,2014,33(12):853-858. 被引量:15
-
6李洪波,刘崇忠.胰头十二指肠切除术联合替吉奥治疗胰腺癌的临床观察[J].中国普通外科杂志,2015,24(9):1232-1236. 被引量:16
-
7张新红,康静波,聂青,徐云科,闫晓梅,张嘉月,展晓宇.射波刀联合替吉奥治疗局部晚期胰腺癌:95例病例-对照研究[J].解放军医学杂志,2016,41(10):848-852. 被引量:2
-
8马金丽,吴涛,陆明.胰十二指肠切除术联合替吉奥治疗胰腺癌的效果及安全性[J].广东医学,2016,37(23):3558-3560. 被引量:9
-
9张元,朱奇.替吉奥单药治疗老年转移性胰腺癌临床观察[J].医学理论与实践,2018,31(11):1626-1628. 被引量:4
-
10邓龑,张勇,李荣清.替吉奥临床应用新进展[J].现代诊断与治疗,2018,29(9):1372-1375. 被引量:5
同被引文献47
-
1孟令新,丁兆军,陈希平.热疗联合腹腔热灌注化疗治疗胰腺癌并腹腔积液的疗效观察[J].中华临床医师杂志(电子版),2011,5(7):1923-1927. 被引量:29
-
2赵玉沛.胰腺癌的诊治现状与展望[J].医学临床研究,2005,22(10):1353-1355. 被引量:6
-
3王成锋,赵平.胰腺癌诊治中应注意的几个问题[J].南方医科大学,2011,6(12):134-135.
-
4高宏,张虹,邵秋菊,吴淑娟,梁军.立体定向放射治疗胰腺癌112例疗效观察[J].现代肿瘤医学,2010,18(1):112-113. 被引量:23
-
5史周印,王艳,孙杰,李伟.高能聚焦超声治疗晚期胰腺癌的临床疗效观察(附21例)[J].现代肿瘤医学,2011,19(2):334-335. 被引量:8
-
6黄炳兴,徐捷.血清肿瘤标志物测定在胰腺癌中的意义[J].现代中西医结合杂志,2011,20(7):873-874. 被引量:14
-
7贾志凌,张宏艳,刘畅,王莉,柴丽娜,张侠,于忠和.血清肿瘤标志物联合检测在胰腺癌诊断中应用[J].中华实用诊断与治疗杂志,2011,25(2):130-131. 被引量:36
-
8罗娅红,于韬,王洋,邱岩,于波,段阳,迟达,何翠菊,刘凡,罗汀.联合应用CT、MRI增强扫描鉴别诊断胰腺癌与慢性胰腺炎[J].磁共振成像,2011,2(1):42-46. 被引量:24
-
9李宁,沈世强,刘建超.血清CA19-9、CA242、CEA及CA125在胰腺癌诊断和预后中的价值[J].中国普外基础与临床杂志,2011,18(3):300-304. 被引量:41
-
10王静波,向子云,詹勇,李嵚,蔡汉寿,朱宇辉.自身免疫性胰腺炎与胰腺癌的CT鉴别诊断价值[J].中国CT和MRI杂志,2011,9(2):45-48. 被引量:36
引证文献5
-
1王学健.胰腺癌诊治近况与进展[J].现代诊断与治疗,2015,26(9):1945-1948.
-
2宋文渊,吴雷,赵红岩,王学国,王槐文.外周血内CA19-9、CA242及CEA对胰腺癌诊断及病理分期评估的价值[J].实用肿瘤杂志,2017,32(1):52-56. 被引量:21
-
3范军达,孙涛.替吉奥单药对比吉西他滨单药一线治疗老年晚期胰腺癌的临床研究[J].中国疗养医学,2017,26(11):1205-1207. 被引量:2
-
4于海涛,曲义坤,于海波,赵斌,李晶,赵晓莲.外周血内基质金属蛋白酶-7、糖类抗原242在直肠癌诊断及术后评估中的价值[J].中国老年学杂志,2018,38(9):2098-2100. 被引量:5
-
5李廷,姜华敏,杨彬.替吉奥单药对比吉西他滨单药一线治疗老年晚期胰腺癌的临床效果分析[J].当代医学,2018,24(13):114-115. 被引量:5
二级引证文献32
-
1邓珠连.血清CA199、CA125与CEA联合检测在胰腺癌病情诊断与预后评估中的指导作用[J].智慧健康,2021,7(10):14-16.
-
2梅杰,左晶,梅家转,肖鹏,刘桂举.血清基质金属蛋白酶7、血清癌胚抗原、糖类抗原199水平与结直肠癌患者临床病理特征的相关性[J].慢性病学杂志,2024(7):1088-1090.
-
3刘涛,刘名霞,崔红,张荣华.中医药治疗胰腺癌临床观察[J].光明中医,2024,39(10):2002-2004.
-
4衡阳,林海.胰腺癌预后因素的研究进展[J].世界最新医学信息文摘,2020(8):164-165. 被引量:3
-
5周颖,吕梦琴,魏睿,奚玲,李飞.血清缓激肽与前列腺癌的相关性研究[J].实用肿瘤杂志,2017,32(3):212-215. 被引量:2
-
6苏德望,付先东,于佳楠,迟男男.血清糖类抗原19-9、癌胚抗原在胆管癌诊断中的应用价值[J].中国实验诊断学,2017,21(10):1693-1695. 被引量:14
-
7韩锋,桑圣刚.糖类抗原CA50和CA242对胰腺癌的诊断价值[J].海南医学,2017,28(24):4029-4032. 被引量:4
-
8钱元,郑松,贾长库.改良FOLFIRINOX与吉西他滨为基础的化疗方案在进展期胰腺癌治疗中的对比研究[J].实用肿瘤杂志,2018,33(3):237-245. 被引量:6
-
9兰军.MRI联合血清CA19-9、CEA、CA125水平检测对胰腺癌诊断价值研究[J].现代消化及介入诊疗,2018,23(4):500-502. 被引量:10
-
10韩庆伟.血清肿瘤抗原199、血清肿瘤抗原242、D-二聚体联合检测在诊断胰腺癌中的临床意义[J].黑龙江医药科学,2018,41(5):125-126. 被引量:7
-
1赵增虎,王明贤,尚培中,刘俊堂.吉西他滨联合替吉奥方案化疗同步调强放疗治疗胰腺癌42例临床观察[J].山西医药杂志,2014,43(14):1695-1697. 被引量:5
-
2林宝钗,邵岚,张贝贝,何春晓,郑蕾,洪卫,娄广媛,张沂平.厄洛替尼在晚期非小细胞肺癌二线和三线治疗疗效比较[J].中国现代医生,2012,50(29):52-54. 被引量:1
-
3鲍明亮,毕清,田青,赵明利,任宏轩.埃克替尼二、三线治疗48例晚期非小细胞肺癌[J].中国肿瘤,2014,23(3):249-252. 被引量:5
-
4周晓娟,王瑾.培美曲塞联合奥沙利铂三线治疗非小细胞肺癌1例[J].肿瘤预防与治疗,2011,24(1):53-54.
-
5马建光,郝翠霞,贾彦民.EP方案联合放疗治疗晚期非小细胞肺癌疗效分析[J].中国基层医药,2003,10(3):221-222. 被引量:3
-
6张殿宝,张宪芬,郭艳珍,张治业,姚俊.吉西他滨联合多西他赛三线治疗复发小细胞肺癌的临床观察[J].中国医药科学,2015,5(19):97-99. 被引量:3
-
7毕延智,宋红蕾,胡岳棣.吉非替尼联合卡培他滨三线治疗晚期结肠癌1例[J].胃肠病学,2012,17(10):639-640. 被引量:4
-
8吴文强.沙立度胺联合VAD方案治疗多发性骨髓瘤22例[J].广西医学,2007,29(8):1264-1265.
-
9熊峰,陶敏,段卫明,王振兴.西妥昔单抗联合伊立替康三线治疗晚期结直肠癌的疗效观察[J].中华肿瘤防治杂志,2008,15(22):1759-1760. 被引量:7
-
10邱大胜,孔祥泉,陈宪.MRI在直肠癌术前分期中的应用[J].临床放射学杂志,2008,27(10):1434-1436. 被引量:1